BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/15/2019 10:17:12 AM | Browse: 1074 | Download: 2035
 |
Received |
|
2019-04-01 01:57 |
|
Peer-Review Started |
|
2019-04-04 07:26 |
|
First Decision by Editorial Office Director |
|
2019-05-08 12:23 |
|
Return for Revision |
|
2019-05-09 02:16 |
|
Revised |
|
2019-05-13 00:53 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-05-13 11:05 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-05-14 01:27 |
|
Articles in Press |
|
2019-05-14 01:27 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-14 09:49 |
|
Publish the Manuscript Online |
|
2019-05-15 10:17 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Minireviews |
| Article Title |
Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Leonardo Pozo, Fatimah Bello, Andres Suarez, Francisco E Ochoa-Martinez, Yamely Mendez, Chelsea H Chang and Salim Surani |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salim Surani, BSc, FACC, FACP, FCCP, MD, Professor, Medical Critical Care Services, Christus Spohn Hospitals-Corpus Christi, 701 Ayers street, Corpus Christi, TX 78404, United States. srsurani@hotmail.com |
| Key Words |
Type 2 diabetes mellitus; Glucagon-like-peptide 1 agonists; Sodium-glucose cotransporter-2 inhibitor; Cardiovascular disease; Major adverse cardiovascular event |
| Core Tip |
Cardiovascular diseases are of significant concern in patients with type 2 diabetes mellitus. Novel therapies offer a new opportunity for cardiovascular risk reduction and add complexity in terms of selecting antihyperglycemic treatment. These pharmacological therapies, however, also have additional considerations. |
| Publish Date |
2019-05-15 10:17 |
| Citation |
Pozo L, Bello F, Suarez A, Ochoa-Martinez FE, Mendez Y, Chang CH, Surani S. Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. World J Diabetes 2019; 10(5): 291-303 |
| URL |
https://www.wjgnet.com/1948-9358/full/v10/i5/291.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v10.i5.291 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
